New article published: How do we develop nanopharmaceuticals under open innovation?

Abstract
It is incumbent on nanomedicine researchers to understand how to develop their ideas into commercial drugs; success to date has not been
as good as funders would have liked. This article attempts to outline, perhaps for the first time, some of the expertise that the pharmaceutical
sector has acquired to facilitate translation. It is hoped this explanation will start to improve the planning required at an early stage to develop
nanopharmaceuticals and to encourage researchers and their institutions to devise a development plan.

>> Read the full article in the Publications section

M.A.W. Eaton, How do we develop nanopharmaceuticals under open innovation? Nanomedicine: NBM 2011;7:371-375,
doi:10.1016/j.nano.2011.05.015